Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support
Identifieur interne : 000440 ( Istex/Corpus ); précédent : 000439; suivant : 000441Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support
Auteurs : Marsha Y. Morgan ; Frédéric Landron ; Philippe LehertSource :
- Alcoholism: Clinical and Experimental Research [ 0145-6008 ] ; 2004-01.
English descriptors
- KwdEn :
Abstract
Abstract: Background: The impact of disease on health‐related quality of life is now well recognized, as is the importance of this variable as a measure of treatment efficacy.
Url:
DOI: 10.1097/01.ALC.0000108652.73143.4B
Links to Exploration step
ISTEX:2DED9DC236C2A94369F429884BF2412428E2C8E4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support</title><author><name sortKey="Morgan, Marsha Y" sort="Morgan, Marsha Y" uniqKey="Morgan M" first="Marsha Y." last="Morgan">Marsha Y. Morgan</name><affiliation><mods:affiliation>Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: mymorgan@rfc.ucl.ac.uk</mods:affiliation></affiliation></author><author><name sortKey="Landron, Frederic" sort="Landron, Frederic" uniqKey="Landron F" first="Frédéric" last="Landron">Frédéric Landron</name><affiliation><mods:affiliation>Merck‐Santé, Lyon, France</mods:affiliation></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation><mods:affiliation>Department of Statistics, Faculty of Economics, FUCAM, Mons, Belgium</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2DED9DC236C2A94369F429884BF2412428E2C8E4</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1097/01.ALC.0000108652.73143.4B</idno><idno type="url">https://api.istex.fr/document/2DED9DC236C2A94369F429884BF2412428E2C8E4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000440</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000440</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support</title><author><name sortKey="Morgan, Marsha Y" sort="Morgan, Marsha Y" uniqKey="Morgan M" first="Marsha Y." last="Morgan">Marsha Y. Morgan</name><affiliation><mods:affiliation>Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: mymorgan@rfc.ucl.ac.uk</mods:affiliation></affiliation></author><author><name sortKey="Landron, Frederic" sort="Landron, Frederic" uniqKey="Landron F" first="Frédéric" last="Landron">Frédéric Landron</name><affiliation><mods:affiliation>Merck‐Santé, Lyon, France</mods:affiliation></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation><mods:affiliation>Department of Statistics, Faculty of Economics, FUCAM, Mons, Belgium</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Alcoholism: Clinical and Experimental Research</title><idno type="ISSN">0145-6008</idno><idno type="eISSN">1530-0277</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-01">2004-01</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="64">64</biblScope><biblScope unit="page" to="77">77</biblScope></imprint><idno type="ISSN">0145-6008</idno></series><idno type="istex">2DED9DC236C2A94369F429884BF2412428E2C8E4</idno><idno type="DOI">10.1097/01.ALC.0000108652.73143.4B</idno><idno type="ArticleID">ACER64</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0145-6008</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alcohol Dependency</term><term>Alcohol Drinking</term><term>Predictor Variables</term><term>Quality of Life</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Abstract: Background: The impact of disease on health‐related quality of life is now well recognized, as is the importance of this variable as a measure of treatment efficacy.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Marsha Y. Morgan</name><affiliations><json:string>Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, University College London, London, United Kingdom</json:string><json:string>E-mail: mymorgan@rfc.ucl.ac.uk</json:string></affiliations></json:item><json:item><name>Frédéric Landron</name><affiliations><json:string>Merck‐Santé, Lyon, France</json:string></affiliations></json:item><json:item><name>Philippe Lehert</name><affiliations><json:string>Department of Statistics, Faculty of Economics, FUCAM, Mons, Belgium</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Alcohol Drinking</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Alcohol Dependency</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Quality of Life</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Predictor Variables</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Treatment Outcome</value></json:item></subject><articleId><json:string>ACER64</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>5.336</score><pdfVersion>1.3</pdfVersion><pdfPageSize>585 x 783 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>175</abstractCharCount><pdfWordCount>9268</pdfWordCount><pdfCharCount>59129</pdfCharCount><pdfPageCount>14</pdfPageCount><abstractWordCount>28</abstractWordCount></qualityIndicators><title>Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support</title><corporate><json:item><name>for the New European Alcoholism Treatment Study Group</name></json:item></corporate><genre><json:string>article</json:string></genre><host><volume>28</volume><publisherId><json:string>ACER</json:string></publisherId><pages><total>14</total><last>77</last><first>64</first></pages><issn><json:string>0145-6008</json:string></issn><issue>1</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1530-0277</json:string></eissn><title>Alcoholism: Clinical and Experimental Research</title><doi><json:string>10.1111/(ISSN)1530-0277</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>substance abuse</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>public health & health services</json:string><json:string>substance abuse</json:string></scienceMetrix></categories><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1097/01.ALC.0000108652.73143.4B</json:string></doi><id>2DED9DC236C2A94369F429884BF2412428E2C8E4</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/2DED9DC236C2A94369F429884BF2412428E2C8E4/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/2DED9DC236C2A94369F429884BF2412428E2C8E4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2DED9DC236C2A94369F429884BF2412428E2C8E4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2004</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support</title><author><orgName>for the New European Alcoholism Treatment Study Group</orgName></author><author xml:id="author-1"><persName><forename type="first">Marsha Y.</forename><surname>Morgan</surname></persName><email>mymorgan@rfc.ucl.ac.uk</email><affiliation>Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, University College London, London, United Kingdom</affiliation></author><author xml:id="author-2"><persName><forename type="first">Frédéric</forename><surname>Landron</surname></persName><affiliation>Merck‐Santé, Lyon, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Philippe</forename><surname>Lehert</surname></persName><affiliation>Department of Statistics, Faculty of Economics, FUCAM, Mons, Belgium</affiliation></author></analytic><monogr><title level="j">Alcoholism: Clinical and Experimental Research</title><idno type="pISSN">0145-6008</idno><idno type="eISSN">1530-0277</idno><idno type="DOI">10.1111/(ISSN)1530-0277</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-01"></date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="64">64</biblScope><biblScope unit="page" to="77">77</biblScope></imprint></monogr><idno type="istex">2DED9DC236C2A94369F429884BF2412428E2C8E4</idno><idno type="DOI">10.1097/01.ALC.0000108652.73143.4B</idno><idno type="ArticleID">ACER64</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Abstract: Background: The impact of disease on health‐related quality of life is now well recognized, as is the importance of this variable as a measure of treatment efficacy.</p></abstract><abstract><p>Methods: Patients from five European countries were enrolled in an open, multicenter, prospective study designed to observe outcome in dependent drinkers treated for 6 months with acamprosate and psychosocial support. Version 1 of the 36‐item Short Form Health Profile (SF‐36v1) questionnaire was administered at inclusion and at 3 and 6 months. Responses were described as handicaps compared with an appropriately matched, healthy reference population. One‐way fixed ANOVA and simultaneous stepwise linear regression analysis were used to identify potential predictors of quality of life at baseline and after treatment.</p></abstract><abstract><p>Results: Baseline SF‐36v1 data were obtained from 1216 patients (mean age, 43 ± 9 years; 77% male). Mean values for all SF‐36v1 dimensions were significantly lower in the patient population than in the normative reference population; the most important deficits were observed in physical and emotional role limitations and in social functioning. The most important predictors of baseline quality of life were severity of alcohol dependence, employment status, psychiatric history, quantity and frequency of alcohol consumption, attendance at Alcoholics Anonymous, global alcohol health status, age, gender, and education. SF‐36v1 data were obtained from 686 patients at 3 months and from 497 at 6 months. Significant improvements were observed in all SF‐36v1 dimensional and summary scores after 3 months of treatment (p < 0.001); further marginal improvements were observed between 3 and 6 months. The most important predictors of quality of life following treatment were the SF‐36v1 profile at baseline, followed by abstinence duration; patients who completed the trial and remained abstinent throughout showed the greatest improvement.</p></abstract><abstract><p>Conclusions: Health‐related quality of life is severly impaired in dependent drinkers. Treatment with acamprosate and psychosocial support, by promoting abstinence, improves the quality of life profile to levels comparable to those observed in healthy individuals.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Alcohol Drinking</term></item><item><term>Alcohol Dependency</term></item><item><term>Quality of Life</term></item><item><term>Predictor Variables</term></item><item><term>Treatment Outcome</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/2DED9DC236C2A94369F429884BF2412428E2C8E4/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1530-0277</doi><issn type="print">0145-6008</issn><issn type="electronic">1530-0277</issn><idGroup><id type="product" value="ACER"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ALCOHOLISM CLINICAL EXPERIMENTAL RESEARCH">Alcoholism: Clinical and Experimental Research</title></titleGroup></publicationMeta><publicationMeta level="part" position="01001"><doi origin="wiley">10.1111/acer.2004.28.issue-1</doi><numberingGroup><numbering type="journalVolume" number="28">28</numbering><numbering type="journalIssue" number="1">1</numbering></numberingGroup><coverDate startDate="2004-01">January 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0006400" status="forIssue"><doi origin="wiley">10.1097/01.ALC.0000108652.73143.4B</doi><idGroup><id type="unit" value="ACER64"></id></idGroup><countGroup><count type="pageTotal" number="14"></count></countGroup><titleGroup><title type="tocHeading1">Diagnosis and Treatment</title></titleGroup><eventGroup><event type="firstOnline" date="2006-05-03"></event><event type="publishedOnlineFinalForm" date="2006-05-03"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-02"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2013-12-31"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="64">64</numbering><numbering type="pageLast" number="77">77</numbering></numberingGroup><correspondenceTo>Marsha Y. Morgan, MB ChB, FRCP, Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, University College London, Rowland Hill St., Hampstead, London NW3 2PF, UK; Fax: 44‐207‐433‐2870; E‐mail: <email>mymorgan@rfc.ucl.ac.uk</email>.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ACER.ACER64.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received for publication July 14, 2003; accepted November 3, 2003.</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="66"></count><count type="linksCrossRef" number="4"></count></countGroup><titleGroup><title type="main">Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Marsha Y.</givenNames><familyName>Morgan</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>Frédéric</givenNames><familyName>Landron</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>Philippe</givenNames><familyName>Lehert</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><groupName>for the New European Alcoholism Treatment Study Group</groupName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="GB"><unparsedAffiliation>Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, University College London, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="FR"><unparsedAffiliation>Merck‐Santé, Lyon, France</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="BE"><unparsedAffiliation>Department of Statistics, Faculty of Economics, FUCAM, Mons, Belgium</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Alcohol Drinking</keyword><keyword xml:id="k2">Alcohol Dependency</keyword><keyword xml:id="k3">Quality of Life</keyword><keyword xml:id="k4">Predictor Variables</keyword><keyword xml:id="k5">Treatment Outcome</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>A<sc>bstract</sc>: </b><b> Background: </b> The impact of disease on health‐related quality of life is now well recognized, as is the importance of this variable as a measure of treatment efficacy.</p><p><b>Methods: </b> Patients from five European countries were enrolled in an open, multicenter, prospective study designed to observe outcome in dependent drinkers treated for 6 months with acamprosate and psychosocial support. Version 1 of the 36‐item Short Form Health Profile (SF‐36v1) questionnaire was administered at inclusion and at 3 and 6 months. Responses were described as handicaps compared with an appropriately matched, healthy reference population. One‐way fixed ANOVA and simultaneous stepwise linear regression analysis were used to identify potential predictors of quality of life at baseline and after treatment.</p><p><b>Results: </b> Baseline SF‐36v1 data were obtained from 1216 patients (mean age, 43 ± 9 years; 77% male). Mean values for all SF‐36v1 dimensions were significantly lower in the patient population than in the normative reference population; the most important deficits were observed in physical and emotional role limitations and in social functioning. The most important predictors of baseline quality of life were severity of alcohol dependence, employment status, psychiatric history, quantity and frequency of alcohol consumption, attendance at Alcoholics Anonymous, global alcohol health status, age, gender, and education. SF‐36v1 data were obtained from 686 patients at 3 months and from 497 at 6 months. Significant improvements were observed in all SF‐36v1 dimensional and summary scores after 3 months of treatment (<i>p</i> < 0.001); further marginal improvements were observed between 3 and 6 months. The most important predictors of quality of life following treatment were the SF‐36v1 profile at baseline, followed by abstinence duration; patients who completed the trial and remained abstinent throughout showed the greatest improvement.</p><p><b>Conclusions: </b> Health‐related quality of life is severly impaired in dependent drinkers. Treatment with acamprosate and psychosocial support, by promoting abstinence, improves the quality of life profile to levels comparable to those observed in healthy individuals.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="n-fnt-1" numbered="no"><p>Funded by Group Lipha without restriction on or control of publication.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support</title></titleInfo><name type="personal"><namePart type="given">Marsha Y.</namePart><namePart type="family">Morgan</namePart><affiliation>Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, University College London, London, United Kingdom</affiliation><affiliation>E-mail: mymorgan@rfc.ucl.ac.uk</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Frédéric</namePart><namePart type="family">Landron</namePart><affiliation>Merck‐Santé, Lyon, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Philippe</namePart><namePart type="family">Lehert</namePart><affiliation>Department of Statistics, Faculty of Economics, FUCAM, Mons, Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>for the New European Alcoholism Treatment Study Group</namePart><description>Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, University College London, London, United KingdomMerck‐Santé, Lyon, FranceDepartment of Statistics, Faculty of Economics, FUCAM, Mons, Belgium</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2004-01</dateIssued><edition>Received for publication July 14, 2003; accepted November 3, 2003.</edition><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">66</extent></physicalDescription><abstract>Abstract: Background: The impact of disease on health‐related quality of life is now well recognized, as is the importance of this variable as a measure of treatment efficacy.</abstract><abstract>Methods: Patients from five European countries were enrolled in an open, multicenter, prospective study designed to observe outcome in dependent drinkers treated for 6 months with acamprosate and psychosocial support. Version 1 of the 36‐item Short Form Health Profile (SF‐36v1) questionnaire was administered at inclusion and at 3 and 6 months. Responses were described as handicaps compared with an appropriately matched, healthy reference population. One‐way fixed ANOVA and simultaneous stepwise linear regression analysis were used to identify potential predictors of quality of life at baseline and after treatment.</abstract><abstract>Results: Baseline SF‐36v1 data were obtained from 1216 patients (mean age, 43 ± 9 years; 77% male). Mean values for all SF‐36v1 dimensions were significantly lower in the patient population than in the normative reference population; the most important deficits were observed in physical and emotional role limitations and in social functioning. The most important predictors of baseline quality of life were severity of alcohol dependence, employment status, psychiatric history, quantity and frequency of alcohol consumption, attendance at Alcoholics Anonymous, global alcohol health status, age, gender, and education. SF‐36v1 data were obtained from 686 patients at 3 months and from 497 at 6 months. Significant improvements were observed in all SF‐36v1 dimensional and summary scores after 3 months of treatment (p < 0.001); further marginal improvements were observed between 3 and 6 months. The most important predictors of quality of life following treatment were the SF‐36v1 profile at baseline, followed by abstinence duration; patients who completed the trial and remained abstinent throughout showed the greatest improvement.</abstract><abstract>Conclusions: Health‐related quality of life is severly impaired in dependent drinkers. Treatment with acamprosate and psychosocial support, by promoting abstinence, improves the quality of life profile to levels comparable to those observed in healthy individuals.</abstract><subject lang="en"><genre>keywords</genre><topic>Alcohol Drinking</topic><topic>Alcohol Dependency</topic><topic>Quality of Life</topic><topic>Predictor Variables</topic><topic>Treatment Outcome</topic></subject><relatedItem type="host"><titleInfo><title>Alcoholism: Clinical and Experimental Research</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0145-6008</identifier><identifier type="eISSN">1530-0277</identifier><identifier type="DOI">10.1111/(ISSN)1530-0277</identifier><identifier type="PublisherID">ACER</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>64</start><end>77</end><total>14</total></extent></part></relatedItem><identifier type="istex">2DED9DC236C2A94369F429884BF2412428E2C8E4</identifier><identifier type="DOI">10.1097/01.ALC.0000108652.73143.4B</identifier><identifier type="ArticleID">ACER64</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000440 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000440 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= TherFamFrancoV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2DED9DC236C2A94369F429884BF2412428E2C8E4
|texte= Improvement in Quality of Life After Treatment for Alcohol Dependence With Acamprosate and Psychosocial Support
}}
| This area was generated with Dilib version V0.6.29. |  |